Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety.

Karulkar A, Jain H, Sidharthan N, Bhurani D, Melinkeri S, Boyella PK, Mehta P, Kaul E, Shah S, P K J, Nair C, Bhargava R, Bagal B, Nayak L, Shetty A, Menon H, Boya RR, Abhinav R, Kalra D, Ravikumar S, Thorat J, Real World Consortium, Purwar S, Shah NN, Fry T, Jain N, Neelapu S, Sengar M, Purwar R

Open source

DOI: 10.1038/s41408-026-01569-w
Published: 2026 Jul 16
Container: Blood cancer journal
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-026-01569-w,
  title = {Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety.},
  author = {Karulkar A and Jain H and Sidharthan N and Bhurani D and Melinkeri S and Boyella PK and Mehta P and Kaul E and Shah S and P K J and Nair C and Bhargava R and Bagal B and Nayak L and Shetty A and Menon H and Boya RR and Abhinav R and Kalra D and Ravikumar S and Thorat J and Real World Consortium and Purwar S and Shah NN and Fry T and Jain N and Neelapu S and Sengar M and Purwar R},
  year = {2026},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-026-01569-w},
  url = {https://doi.org/10.1038/s41408-026-01569-w}
}

RIS

TY  - JOUR
TI  - Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety.
AU  - Karulkar A
AU  - Jain H
AU  - Sidharthan N
AU  - Bhurani D
AU  - Melinkeri S
AU  - Boyella PK
AU  - Mehta P
AU  - Kaul E
AU  - Shah S
AU  - P K J
AU  - Nair C
AU  - Bhargava R
AU  - Bagal B
AU  - Nayak L
AU  - Shetty A
AU  - Menon H
AU  - Boya RR
AU  - Abhinav R
AU  - Kalra D
AU  - Ravikumar S
AU  - Thorat J
AU  - Real World Consortium
AU  - Purwar S
AU  - Shah NN
AU  - Fry T
AU  - Jain N
AU  - Neelapu S
AU  - Sengar M
AU  - Purwar R
PY  - 2026
JO  - Blood cancer journal
DO  - 10.1038/s41408-026-01569-w
UR  - https://doi.org/10.1038/s41408-026-01569-w
ER  -

APA

A, K., H, J., N, S., D, B., S, M., PK, B., P, M., E, K., S, S., J, P. K., C, N., R, B., B, B., L, N., A, S., H, M., RR, B., R, A., D, K., S, R., J, T., Consortium, R. W., S, P., NN, S., T, F., N, J., S, N., M, S., & R, P. (2026). Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety.. Blood cancer journal. https://doi.org/10.1038/s41408-026-01569-w

Source records

pubmed · retrieved 2026-09-26T05:29:25.496Z
europe-pmc · retrieved 2026-09-26T05:29:25.514Z